---
document_datetime: 2025-12-29 11:44:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/givlaari.html
document_name: givlaari.html
version: success
processing_time: 0.0984695
conversion_datetime: 2025-12-30 00:51:05.874933
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Givlaari

[RSS](/en/individual-human-medicine.xml/67285)

##### Authorised

This medicine is authorised for use in the European Union

givosiran Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Givlaari](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76399)
- [More information on Givlaari](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Givlaari is a medicine for treating acute hepatic porphyria in patients aged 12 years or over.

Acute hepatic porphyria is a rare genetic condition in which the liver cannot properly produce a substance called haem. As a result, substances used to make haem build up in the body, causing attacks of severe abdominal pain, vomiting and nervous system disorders.

Acute hepatic porphyria is rare, and Givlaari was designated an 'orphan medicine' (a medicine used in rare diseases) on 29 August 2016.

Givlaari contains the active substance givosiran.

Expand section

Collapse section

## How is Givlaari used?

Givlaari is given by injection under the skin once a month. The dose depends on the patient's weight.

The medicine can only be obtained with a prescription and treatment should be started by a healthcare professional experienced in managing the condition. For more information about using Givlaari, see the package leaflet or contact your doctor or pharmacist.

## How does Givlaari work?

The active substance in Givlaari, givosiran, is a synthetic small interfering RNA (a type of genetic material) that works by reducing the production of an enzyme involved in an early step of haem production in the liver. This prevents the build-up of the substances that cause the symptoms of the condition.

## What benefits of Givlaari have been shown in studies?

Givlaari was more effective than placebo (a dummy treatment) in reducing the yearly number of serious porphyria attacks. In a main study involving 94 patients, those who received Givlaari had on average 3 serious attacks of symptoms per year compared with 13 in those receiving placebo.

## What are the risks associated with Givlaari?

The most common side effects with Givlaari (which may affect more than 1 in 5 people) are reactions at the site of the injection, nausea (feeling sick) and tiredness. For the full list of side effects and restrictions, see the package leaflet.

## Why is Givlaari authorised in the EU?

A main study has shown that Givlaari is effective at reducing porphyria attacks. The side effects of Givlaari treatment were mostly mild and moderate and most resolved during the study.

The European Medicines Agency therefore decided that Givlaari's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Givlaari?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Givlaari have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Givlaari are continuously monitored. Side effects reported with Givlaari are carefully evaluated and any necessary action taken to protect patients.

## Other information about Givlaari

Givlaari received a marketing authorisation valid throughout the EU on 2 March 2020.

Givlaari : EPAR - Medicine overview

Reference Number: EMA/62114/2020

English (EN) (117.73 KB - PDF)

**First published:** 09/03/2020

[View](/en/documents/overview/givlaari-epar-medicine-overview_en.pdf)

Givlaari : EPAR - Risk-management-plan summary

English (EN) (114.11 KB - PDF)

**First published:** 09/03/2020

**Last updated:** 18/12/2024

[View](/en/documents/rmp-summary/givlaari-epar-risk-management-plan-summary_en.pdf)

## Product information

Givlaari : EPAR - Product information

English (EN) (350.78 KB - PDF)

**First published:** 09/03/2020

**Last updated:** 08/05/2025

[View](/en/documents/product-information/givlaari-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-383)

български (BG) (438.45 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/bg/documents/product-information/givlaari-epar-product-information_bg.pdf)

español (ES) (360.06 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/es/documents/product-information/givlaari-epar-product-information_es.pdf)

čeština (CS) (434.38 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/cs/documents/product-information/givlaari-epar-product-information_cs.pdf)

dansk (DA) (365.88 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/da/documents/product-information/givlaari-epar-product-information_da.pdf)

Deutsch (DE) (378.2 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/de/documents/product-information/givlaari-epar-product-information_de.pdf)

eesti keel (ET) (355.6 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/et/documents/product-information/givlaari-epar-product-information_et.pdf)

ελληνικά (EL) (540.79 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/el/documents/product-information/givlaari-epar-product-information_el.pdf)

français (FR) (421.82 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/fr/documents/product-information/givlaari-epar-product-information_fr.pdf)

hrvatski (HR) (427.01 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/hr/documents/product-information/givlaari-epar-product-information_hr.pdf)

íslenska (IS) (370 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/is/documents/product-information/givlaari-epar-product-information_is.pdf)

italiano (IT) (353.87 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/it/documents/product-information/givlaari-epar-product-information_it.pdf)

latviešu valoda (LV) (423.09 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/lv/documents/product-information/givlaari-epar-product-information_lv.pdf)

lietuvių kalba (LT) (392.82 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/lt/documents/product-information/givlaari-epar-product-information_lt.pdf)

magyar (HU) (436.61 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/hu/documents/product-information/givlaari-epar-product-information_hu.pdf)

Malti (MT) (440.23 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/mt/documents/product-information/givlaari-epar-product-information_mt.pdf)

Nederlands (NL) (358.26 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/nl/documents/product-information/givlaari-epar-product-information_nl.pdf)

norsk (NO) (350.15 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/no/documents/product-information/givlaari-epar-product-information_no.pdf)

polski (PL) (441.43 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/pl/documents/product-information/givlaari-epar-product-information_pl.pdf)

português (PT) (350.98 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/pt/documents/product-information/givlaari-epar-product-information_pt.pdf)

română (RO) (410.75 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/ro/documents/product-information/givlaari-epar-product-information_ro.pdf)

slovenčina (SK) (431.62 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/sk/documents/product-information/givlaari-epar-product-information_sk.pdf)

slovenščina (SL) (406.27 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/sl/documents/product-information/givlaari-epar-product-information_sl.pdf)

Suomi (FI) (358.06 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/fi/documents/product-information/givlaari-epar-product-information_fi.pdf)

svenska (SV) (349.97 KB - PDF)

**First published:**

09/03/2020

**Last updated:**

08/05/2025

[View](/sv/documents/product-information/givlaari-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000265950 08/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Givlaari : EPAR - All authorised presentations

English (EN) (38.29 KB - PDF)

**First published:** 09/03/2020

[View](/en/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-419)

български (BG) (59.31 KB - PDF)

**First published:**

09/03/2020

[View](/bg/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_bg.pdf)

español (ES) (43.38 KB - PDF)

**First published:**

09/03/2020

[View](/es/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_es.pdf)

čeština (CS) (58.92 KB - PDF)

**First published:**

09/03/2020

[View](/cs/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (44.81 KB - PDF)

**First published:**

09/03/2020

[View](/da/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.77 KB - PDF)

**First published:**

09/03/2020

[View](/de/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (42.41 KB - PDF)

**First published:**

09/03/2020

[View](/et/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.66 KB - PDF)

**First published:**

09/03/2020

[View](/el/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_el.pdf)

français (FR) (43.39 KB - PDF)

**First published:**

09/03/2020

[View](/fr/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (41.95 KB - PDF)

**First published:**

09/03/2020

[View](/hr/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (44.07 KB - PDF)

**First published:**

09/03/2020

[View](/is/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_is.pdf)

italiano (IT) (42.82 KB - PDF)

**First published:**

09/03/2020

[View](/it/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (59.49 KB - PDF)

**First published:**

09/03/2020

[View](/lv/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (52.41 KB - PDF)

**First published:**

09/03/2020

[View](/lt/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.82 KB - PDF)

**First published:**

09/03/2020

[View](/hu/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.18 KB - PDF)

**First published:**

09/03/2020

[View](/mt/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (44.03 KB - PDF)

**First published:**

09/03/2020

[View](/nl/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (44.05 KB - PDF)

**First published:**

09/03/2020

[View](/no/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_no.pdf)

polski (PL) (62.58 KB - PDF)

**First published:**

09/03/2020

[View](/pl/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_pl.pdf)

português (PT) (40.28 KB - PDF)

**First published:**

09/03/2020

[View](/pt/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_pt.pdf)

română (RO) (59.42 KB - PDF)

**First published:**

09/03/2020

[View](/ro/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (42.83 KB - PDF)

**First published:**

09/03/2020

[View](/sk/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (40.1 KB - PDF)

**First published:**

09/03/2020

[View](/sl/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.52 KB - PDF)

**First published:**

09/03/2020

[View](/fi/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (43.36 KB - PDF)

**First published:**

09/03/2020

[View](/sv/documents/all-authorised-presentations/givlaari-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Givlaari Active substance Givosiran International non-proprietary name (INN) or common name givosiran Therapeutic area (MeSH) Porphyrias, Hepatic Anatomical therapeutic chemical (ATC) code A16AX16

### Pharmacotherapeutic group

Various alimentary tract and metabolism products

### Therapeutic indication

Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.

## Authorisation details

EMA product number EMEA/H/C/004775

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Alnylam Netherlands B.V.

Antonio Vivaldistraat 150

Opinion adopted 30/01/2020 Marketing authorisation issued 02/03/2020 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Givlaari : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (140.37 KB - PDF)

**First published:** 08/05/2025

[View](/en/documents/procedural-steps-after/givlaari-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Givlaari : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (152.31 KB - PDF)

**First published:** 18/03/2021

**Last updated:** 08/05/2025

[View](/en/documents/procedural-steps-after/givlaari-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Givlaari-PSUSA-00010839-202011 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/581034/2021

English (EN) (124.66 KB - PDF)

**First published:** 12/10/2021

[View](/en/documents/scientific-conclusion/givlaari-psusa-00010839-202011-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Givlaari : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/70703/2020

English (EN) (2.43 MB - PDF)

**First published:** 09/03/2020

[View](/en/documents/assessment-report/givlaari-epar-public-assessment-report_en.pdf)

Givlaari : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-424091

English (EN) (391.08 KB - PDF)

**First published:** 09/03/2020

[View](/en/documents/orphan-maintenance-report/givlaari-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

CHMP summary of positive opinion for Givlaari

Adopted

Reference Number: EMA/CHMP/38428/2020

English (EN) (134.32 KB - PDF)

**First published:** 31/01/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-givlaari_en.pdf)

#### News on Givlaari

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2020) 31/01/2020

[First treatment for acute hepatic porphyria](/en/news/first-treatment-acute-hepatic-porphyria) 31/01/2020

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Givlaari : EPAR - Product information - tracked changes

English (EN) (92.83 KB - DOCX)

**First published:** 12/05/2025

[View](/en/documents/product-information-tracked-changes/givlaari-epar-product-information-tracked-changes_en.docx)

#### More information on Givlaari

- [EU/3/16/1731 - orphan designation for treatment of acute hepatic porphyria](/en/medicines/human/orphan-designations/eu-3-16-1731)
- [ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP) - post-authorisation study](https://catalogues.ema.europa.eu/study/43202)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 08/05/2025

## Share this page

[Back to top](#main-content)